Moreover, given that kinase inhibitors usually show milder toxicity than cytotoxic chemotherapy, the current Japanese Lung Cancer Society guideline for stage IV NSCLC recommends (level 1C) the use of any EGFR-TKI for the first-line treatment of elderly patients with a driver oncogene [8]. Here, EGFR is linked to non-small cell lung carcinoma.